Drugs / BMS-986251
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03329885 | Nov 2017 → Jun 2018 | ankylosing spondylitis, inflammatory bowel disease, metabolic dysfunction-associated steatohepatitis, psoriasis | Bristol-Myers Squibb | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986251 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03329885 ↗ |
| Modality | Small molecule | — CHEMBL4634542 ↗ |
| Route | Oral | “Escalating oral dose” NCT03329885 ↗ |